Galecto, Inc. Common Stock
GLTOGalecto, Inc. (GLTO) is a biotechnology company focused on developing and commercializing treatments for fibrosis and cancer. It specializes in small molecule therapeutics targeting galectin proteins, which play a role in various pathological processes. The company's therapies aim to address unmet medical needs in diseases characterized by fibrosis and tumor progression.
Company News
Galecto's Board of Directors approved granting 312,535 non-qualified stock options to a new employee at an exercise price of $32.00, with a vesting schedule starting from the first anniversary of the grant date.
Galecto Inc. acquired Damora Therapeutics, expanding its blood cancer pipeline and securing $284.9 million in funding through a private placement, with plans to advance multiple therapeutic programs targeting myeloproliferative neoplasms and acute myeloid leukemia.
Galecto acquired Damora Therapeutics, a biotechnology company developing therapies for myeloproliferative neoplasms, in a transaction accompanied by a $285 million private investment that positions the company to advance potentially breakthrough treatments for blood cancers.
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.
Galecto, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences, including the Oppenheimer 35th Annual Healthcare Life Sciences Conference, Leerink Partners Global Healthcare Conference, and 37th Annual ROTH Conference.
